{"id":"NCT03935217","sponsor":"Lupin Research Inc","briefTitle":"A Phase 3 Study of Solosec速 for the Treatment of Trichomoniasis","officialTitle":"Multi-center, Prospective, Randomized, Placebo-Controlled, Delayed Treatment, Double-Blind Study to Evaluate the Effectiveness and Safety of a Single Oral Dose of Solosec速 for the Treatment of Trichomoniasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-23","primaryCompletion":"2020-03-02","completion":"2020-03-25","firstPosted":"2019-05-02","resultsPosted":"2023-10-04","lastUpdate":"2023-10-04"},"enrollment":147,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Trichomonas Infection"],"interventions":[{"type":"DRUG","name":"Secnidazole","otherNames":["Solosec速"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Solosec (containing 2 grams of secnidazole)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral dose of Solosec速 containing 2 grams of secnidazole in female patients with trichomoniasis.","primaryOutcome":{"measure":"Microbiological Cure at the TOC Visit","timeFrame":"Study Day 6-12","effectByArm":[{"arm":"Solosec 2 Grams","deltaMin":59,"sd":null},{"arm":"Placebo","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":["37550019","33768237"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":74},"commonTop":["Headache","Nausea","Diarrhea","Vulvovagnial candidiasis","Trichomoniasis"]}}